MORRIS PLAINS, N.J., July 21, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that U.S. patent 7,563,433 covering methods and compositions for fluorine-18 (F-18) labeling of proteins, peptides and other molecules will issue today. The allowed claims cover the novel method for attaching F-18 to peptides via a conjugate with aluminum or other metals recently published by the Company in June, 2009, issue of The Journal of Nuclear Medicine. At the 2009 annual meeting of the Society of Nuclear Medicine, using the new labeling method, F-18 labeled peptides were shown to be stable enough to produce exceptional positron-emission tomography (PET) images of receptor-expressing tumors in animals. The new patent provides coverage until 2027.
